[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-adult-onset\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-adult-onset":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100642861","hydration-intervention-to-decrease-side-effects-associated-with-glp---1-ra-therapy-100642861",false,"NCT07641361","Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy","Hydration Intervention to Address Dehydration Associated With Use of GLP-1 Based Medications","Inclusion Criteria:\n\n* Adults aged 18-60\n* Recently prescribed a GLP-1RA (within one week of prescription)\n* Fluent in English\n* Willing to complete the study protocol\n\nExclusion Criteria:\n\n* Children and adults \\> 60 years of age\n* Those not taking a GLP-1RA\n* Those who have been on a GLP-1RA longer than one week\n* Not fluent in English\n* Those who are pregnant or planning on becoming pregnant during the duration of the study\n* Unwilling to comply with study protocol\n* People with cardiac implants","ALL","18 Years","60 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.",[27,28,29,30,31],"Obesity & Overweight","Type 2 Diabetes","Type 2 Diabetes (Adult Onset)","Obesity Type 2 Diabetes Mellitus","Dehydration",[33,34,35,31,36,37],"Hydration","GLP - 1 RA","GLP - 1 RA therapy","Hydration biomarkers","GLP - 1 RA side effects","RECRUITING","2026-06-08",{"date":41,"type":42},"2026-06-11","ACTUAL",{"date":44,"type":21},"2026-06-15",{"date":46,"type":21},"2027-02-01",{"name":48,"class":49},"State University of New York at Buffalo","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":5},"100535051","phase-3-comparative-effectiveness-of-two-initial-combination-therapies-in-patients-with-recent-onset-diabetes-100535051","NCT06246799","Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset Diabetes","Inclusion Criteria:\n\n1. Ability of subject to understand and the willingness to sign a written informed consent document.\n2. Males and females; Age 18-75 years\n3. Recently (within 5 years) diagnosed Type 2 Diabetes Mellitus (T2DM) patients\n4. Drug naïve or receiving metformin monotherapy\n5. HbA1c \\>6.5% (no limit on upper HbA1c value);\n6. Willingness to adhere to the investigational product regimen\n7. Good general health\n8. Stable body weight over the preceding 3 months\n9. Agreement to adhere to Lifestyle Considerations throughout study duration.\n\nExclusion Criteria:\n\n1. positive anti-GAD (antibodies to glutamic acid decarboxylase)\n2. pregnancy or plan of becoming pregnant\n3. evidence of proliferative diabetic retinopathy,\n4. plasma creatinine \\>1.4 females or \\>1.5 males;\n5. presence of congestive heart failure (CHF);\n6. history of cancer (\\\u003C5 years);\n7. prior history of pancreatitis,\n8. bladder cancer or family history of thyroid tumors;\n9. presence of hematuria in the urine analysis.","75 Years",{"count":60,"type":21},256,[62],"PHASE3","The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.",[29],"2026-03-09",{"date":67,"type":42},"2026-03-10",{"date":69,"type":42},"2024-11-07",{"date":71,"type":21},"2029-06-30",{"name":73,"class":49},"The University of Texas Health Science Center at San Antonio"]